<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Emerg Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Emerg Med</journal-id><journal-title-group><journal-title>BMC Emergency Medicine</journal-title></journal-title-group><issn pub-type="epub">1471-227X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28851296</article-id><article-id pub-id-type="pmc">5576372</article-id><article-id pub-id-type="publisher-id">138</article-id><article-id pub-id-type="doi">10.1186/s12873-017-0138-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Design and rationale of the Procalcitonin Antibiotic Consensus Trial (ProACT), a multicenter randomized trial of procalcitonin antibiotic guidance in lower respiratory tract infection</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Huang</surname><given-names>David T.</given-names></name><address><phone>(412) 647 6818</phone><email>huangdt@upmc.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Angus</surname><given-names>Derek C.</given-names></name><address><email>angusdc@upmc.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Chung-Chou H.</given-names></name><address><email>changj@pitt.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Doi</surname><given-names>Yohei</given-names></name><address><email>doiy@upmc.edu</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Fine</surname><given-names>Michael J.</given-names></name><address><email>Michael.Fine@va.gov</email></address><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Kellum</surname><given-names>John A.</given-names></name><address><email>kellum@pitt.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Peck-Palmer</surname><given-names>Octavia M.</given-names></name><address><email>palmerom@upmc.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Pike</surname><given-names>Francis</given-names></name><address><email>francis.pike@yahoo.com</email></address><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Weissfeld</surname><given-names>Lisa A.</given-names></name><address><email>lisa.weissfeld@statcollab.com</email></address><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Yabes</surname><given-names>Jonathan</given-names></name><address><email>jgy2@pitt.edu</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Yealy</surname><given-names>Donald M.</given-names></name><address><email>yealydm@upmc.edu</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><collab>on behalf of the ProACT Investigators<contrib-group><contrib contrib-type="author"><name><surname>Donnino</surname><given-names>Michael</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hou</surname><given-names>Peter</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sherwin</surname><given-names>Robert</given-names></name></contrib><contrib contrib-type="author"><name><surname>Holst</surname><given-names>John</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rafferty</surname><given-names>Colleen</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rodgers</surname><given-names>Daniel</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dachman</surname><given-names>William</given-names></name></contrib><contrib contrib-type="author"><name><surname>LoVecchio</surname><given-names>Frank</given-names></name></contrib><contrib contrib-type="author"><name><surname>Filbin</surname><given-names>Michael</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fine</surname><given-names>Jonathan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hammel</surname><given-names>Jean</given-names></name></contrib><contrib contrib-type="author"><name><surname>Exline</surname><given-names>Matthew</given-names></name></contrib><contrib contrib-type="author"><name><surname>Southerland</surname><given-names>Lauren</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kurz</surname><given-names>Michael</given-names></name></contrib><contrib contrib-type="author"><name><surname>McCullum</surname><given-names>David</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lotfipour</surname><given-names>Shahram</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wilkerson</surname><given-names>Gentry</given-names></name></contrib><contrib contrib-type="author"><name><surname>Prunty</surname><given-names>Heather</given-names></name></contrib><contrib contrib-type="author"><name><surname>Suffoletto</surname><given-names>Brian</given-names></name></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>Aaron</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jovin</surname><given-names>Franziska</given-names></name></contrib></contrib-group></collab></contrib><aff id="Aff1"><label>1</label>The CRISMA (Clinical Research, Investigation, and Systems Modeling of Acute Illness) Center, Pittsburgh, PA USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9000</institution-id><institution-id institution-id-type="GRID">grid.21925.3d</institution-id><institution>Department of Critical Care Medicine, </institution><institution>University of Pittsburgh, </institution></institution-wrap>Room 606B Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15261 USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9000</institution-id><institution-id institution-id-type="GRID">grid.21925.3d</institution-id><institution>Department of Emergency Medicine, </institution><institution>University of Pittsburgh, </institution></institution-wrap>Pittsburgh, PA USA </aff><aff id="Aff4"><label>4</label>The MACRO (Multidisciplinary Acute Care Research Organization) Center, Pittsburgh, PA USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9000</institution-id><institution-id institution-id-type="GRID">grid.21925.3d</institution-id><institution>Division of General Internal Medicine, </institution><institution>University of Pittsburgh, </institution></institution-wrap>Pittsburgh, PA USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9000</institution-id><institution-id institution-id-type="GRID">grid.21925.3d</institution-id><institution>Division of Infectious Diseases, </institution><institution>University of Pittsburgh, </institution></institution-wrap>Pittsburgh, PA USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0420 3665</institution-id><institution-id institution-id-type="GRID">grid.413935.9</institution-id><institution>Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, </institution></institution-wrap>Pittsburgh, PA USA </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9000</institution-id><institution-id institution-id-type="GRID">grid.21925.3d</institution-id><institution>Department of Pathology, </institution><institution>University of Pittsburgh, </institution></institution-wrap>Pittsburgh, PA USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 2220 2544</institution-id><institution-id institution-id-type="GRID">grid.417540.3</institution-id><institution>Eli Lilly and Company, </institution></institution-wrap>Indianapolis, IN USA </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.437929.2</institution-id><institution>Statistics Collaborative, Inc., </institution></institution-wrap>Washington, DC USA </aff></contrib-group><pub-date pub-type="epub"><day>29</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>29</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>17</volume><elocation-id>25</elocation-id><history><date date-type="received"><day>21</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>9</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Overuse of antibiotics is a major public health problem, contributing to growing antibiotic resistance. Procalcitonin has been reported to be commonly elevated in bacterial, but not viral infection. Multiple European trials found procalcitonin-guided care reduced antibiotic use in lower respiratory tract infection, with no apparent harm. However, applicability to US practice is limited due to trial design features impractical in the US, between-country differences, and residual safety concerns.</p></sec><sec><title>Methods</title><p id="Par2">The Procalcitonin Antibiotic Consensus Trial (ProACT) is a multicenter randomized trial to determine the impact of a procalcitonin antibiotic prescribing guideline, implemented with basic reproducible strategies, in US patients with lower respiratory tract infection.</p></sec><sec><title>Discussion</title><p id="Par3">We describe the trial methods using the Consolidated Standards of Reporting Trials (CONSORT) framework, and the rationale for key design decisions, including choice of eligibility criteria, choice of control arm, and approach to guideline implementation.</p></sec><sec><title>Trial registration</title><p id="Par4">ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02130986">NCT02130986</ext-link>. Registered May 1, 2014.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Procalcitonin</kwd><kwd>Biomarkers</kwd><kwd>Respiratory tract infections</kwd><kwd>Clinical trial</kwd><kwd>Anti-bacterial agents</kwd><kwd>Methods (MeSH)</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>1R01GM101197-01A1</award-id><award-id>1R34GM102696-01</award-id><principal-award-recipient><name><surname>Huang</surname><given-names>David T.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par12">Whether or not to administer antibiotics is a common and challenging clinical decision. Clinical presentations for infectious and non-infectious conditions overlap, and current diagnostic tests are inadequate. Given fears of untreated bacterial illness, clinicians often default to a decision to prescribe antibiotics. This pattern drives antibiotic overuse [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>] and resistance [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>], despite considerable efforts to change behavior [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. Lower respiratory tract infection (LRTI) is arguably the most important example of this pattern. It is extremely common, but presentation is non-specific, making it difficult for clinicians to distinguish a bacterial from viral etiology or to distinguish LRTI from non-infectious conditions with similar signs and symptoms [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par13">Host response to bacterial infection includes broad expression of procalcitonin from both immune and parenchymal cells, resulting in elevated serum concentration [<xref ref-type="bibr" rid="CR9">9</xref>]. Viral infection does not appear to induce the same response [<xref ref-type="bibr" rid="CR10">10</xref>]. The magnitude of elevation correlates with the severity of bacterial infection and decreasing concentrations over time correlate with resolution of infection [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. Consequently, Mueller and colleagues tested whether the use of procalcitonin, folded into a treatment recommendation guideline, could help clinicians curb antibiotic use. Multiple European trials reported procalcitonin-guided care reduced antibiotic use in LRTI, with no apparent harm [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par133">However, applicability to US practice is limited due to trial design features impractical in the US, between-country differences, and residual safety concerns [<xref ref-type="bibr" rid="CR19">19</xref>]. For example, in the largest trial, the treating physicians enrolled patients in the emergency department (ED) and were only allowed to overrule procalcitonin guidance after consulting with the study center [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. In the US, ED volume and acuity are high and increasing [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>], and physicians highly value autonomy and resist protocolization [<xref ref-type="bibr" rid="CR23">23</xref>]. Control group antibiotic duration and hospital length of stay were also twice that of current guideline recommendations [<xref ref-type="bibr" rid="CR24">24</xref>] and US practice [<xref ref-type="bibr" rid="CR25">25</xref>], and there is a growing trend towards short antibiotic courses [<xref ref-type="bibr" rid="CR26">26</xref>]. In the only US trial, published in 2015, there was no significant difference in antibiotic use in a single center study of hospitalized LRTI patients randomized to standard care versus procalcitonin-guided care [<xref ref-type="bibr" rid="CR27">27</xref>]. The incremental value of procalcitonin beyond best practice promotion of current guidelines [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], and in clinically obvious cases [<xref ref-type="bibr" rid="CR30">30</xref>], has therefore been questioned.</p><p id="Par14">Current guidelines for procalcitonin guided LRTI care vary from low to moderately strong recommendation [<xref ref-type="bibr" rid="CR31">31</xref>] to recommendation against routine adoption [<xref ref-type="bibr" rid="CR32">32</xref>], reflecting indeterminate evidence. In February 2017, the US Food and Drug Administration approved procalcitonin to help determine if antibiotic treatment should be started or stopped in LRTI, based on a meta-analysis by the requesting sponsor (bioM<italic>&#x000e9;</italic>rieux, Marcy-l&#x02019;&#x000c9;toile, France), while noting the primary limitation of the meta-analysis was a lack of US clinical trial sites [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par15">In November 2014, ProACT (Procalcitonin Antibiotic Consensus Trial, NCT02130986) began enrollment in the United States. ProACT seeks to determine the effect of a procalcitonin guideline on antibiotic exposure and adverse outcomes in clinically diagnosed LRTI, using a study design generalizable to US healthcare. This manuscript provides the trial methodology using the Consolidated Standards of Reporting Trials (CONSORT) framework [<xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>], and discusses key design challenges and their resolution.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Trial methodology and rationale</title><p id="Par16">ProACT is a patient-level, 1:1 randomized, parallel group, 14-center US trial comparing a procalcitonin-guided antibiotic prescribing guideline (implemented with basic reproducible strategies, including education, embedment into the electronic health record, and reminders) to usual care. We chose to test this guideline in a usual care environment where best practice exists and is promoted, in patient encounters with clinical uncertainty regarding antibiotic prescription, and with a design that embraces clinician autonomy. We summarize trial methods in Tables <xref rid="Tab1" ref-type="table">1</xref>, <xref rid="Tab2" ref-type="table">2</xref>, <xref rid="Tab3" ref-type="table">3</xref>, <xref rid="Tab4" ref-type="table">4</xref> and <xref rid="Tab5" ref-type="table">5</xref>. The following CONSORT-Methods sections provide additional details and context.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Eligibility criteria</p></caption><table frame="hsides" rules="groups"><thead><tr><th>CONSORT</th><th>ProACT</th></tr></thead><tbody><tr><td>Inclusion criteria</td><td>&#x02265; 18&#x000a0;years of age<break/>A primary clinical diagnosis in the ED of acute LRTI (&#x0003c; 28&#x000a0;days duration) <sup>a</sup>
<break/>Clinician willing to consider procalcitonin in antibiotic decision making</td></tr><tr><td>Exclusion criteria</td><td>Conditions where physicians are unlikely to withhold antibiotics<break/>&#x02003;Systemic antibiotics before ED presentation<break/>&#x02003;&#x02003;a. All prophylactic antibiotic regimens, or<break/>&#x02003;&#x02003;b. Received &#x0003e;1 dose within 72&#x000a0;h prior to ED presentation<break/>&#x02003;Current vasopressor use<break/>&#x02003;Mechanical ventilation (via endotracheal tube)<break/>&#x02003;Known severe immunosuppression <sup>b</sup>
<break/>&#x02003;Accompanying non-respiratory infections<break/>&#x02003;Known lung abscess or empyema<break/>Conditions where PCT can be &#x0003e;0.25 &#x003bc;g/L without infection<break/>&#x02003;Chronic dialysis<break/>&#x02003;Metastatic cancer<break/>&#x02003;Surgery in the past 7&#x000a0;days (excluding minor surgery such as skin biopsy)<break/>Conditions rendering follow-up difficult<break/>&#x02003;Incarcerated or homeless<break/>&#x02003;Enrolled in ProACT in the past 30&#x000a0;days</td></tr></tbody></table><table-wrap-foot><p>
<italic>ED</italic> emergency department, <italic>LRTI</italic> lower respiratory tract infection</p><p>
<sup>a</sup>post-enrollment, LRTI is classified into the following categories (i) community acquired pneumonia, (ii) chronic obstructive pulmonary disease exacerbation, (iii) acute asthma exacerbation, (iv) acute bronchitis, (v) other LRTI</p><p>
<sup>b</sup>known CD4&#x000a0;&#x0003c;&#x000a0;200/mm<sup>3</sup>, transplant patient on immunosuppressive medications, absolute neutrophil count &#x0003c;500&#x000a0;mm<sup>3</sup>
</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Interventions</p></caption><table frame="hsides" rules="groups"><thead><tr><th>CONSORT</th><th>ProACT</th></tr></thead><tbody><tr><td colspan="2">Study arms</td></tr><tr><td>&#x02003;Usual care</td><td>All care and decisions by existing care providers<break/>National LRTI guidelines disseminated<break/>No procalcitonin provided</td></tr><tr><td>&#x02003;Intervention</td><td>All care and decisions by existing care providers<break/>National LRTI guidelines disseminated<break/>Procalcitonin provided in ED, and if hospitalized, 6&#x02013;24&#x000a0;h later, and on Days 3, 5, 7. <sup>a</sup>
</td></tr><tr><td>Standardization</td><td>Standardized teaching material at start-up and refresher meetings, frequently asked questions, access to coordinating center and principal investigator 24/7<break/>Study website, center visits and newsletters<break/>Center monitoring</td></tr><tr><td>Adherence</td><td>Regular adherence reports of procalcitonin sample time collection, time to clinician notification, procalcitonin guideline adherence, and feedback to individual centers</td></tr></tbody></table><table-wrap-foot><p>
<italic>ED</italic> emergency department, <italic>LRTI</italic> lower respiratory tract infection</p><p>
<sup>a</sup>serial blood draws only occur in hospitalized patients on antibiotics</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><th>CONSORT</th><th>ProACT</th></tr></thead><tbody><tr><td colspan="2">Outcomes</td></tr><tr><td>&#x02003;Primary</td><td>Total antibiotic exposure, defined as the total number of antibiotic-days by Day 30 <sup>a</sup>
<break/>A combined endpoint of adverse outcomes that could be attributable to withholding antibiotics in LRTI, that occur by study Day 30 <sup>b</sup>:<break/>&#x02003;i. death<break/>&#x02003;ii. septic shock (vasopressor use for &#x0003e;1&#x000a0;h)<break/>&#x02003;iii. Mechanical ventilation (via endotracheal tube)<break/>&#x02003;iv. renal failure (KDIGO, stage 3) [<xref ref-type="bibr" rid="CR50">50</xref>]<break/>&#x02003;v. lung abscess/empyema<break/>&#x02003;vi. development of pneumonia in non-pneumonia LRTI<break/>&#x02003;vii. Subsequent hospitalization</td></tr><tr><td>&#x02003;Secondary</td><td>Antibiotic initiation by the initial ED clinician<break/>Hospital length of stay<break/>90d and 1&#x000a0;year mortality<break/>Intensive care unit admission<break/>Subsequent ED visits<break/>Quality of life (Airway Questionnaire 20) [<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td>&#x02003;Data quality methods</td><td>Standardized data collection and recording<break/>Web-based DCF with built-in logic checks, automatic data queries, and streamlined user interface<break/>Periodic DCF checks to monitor data irregularities and protocol compliance<break/>Study coordinator DCF training and periodic conference calls<break/>Center monitoring visits and review of source documents</td></tr></tbody></table><table-wrap-foot><p>
<italic>LRTI</italic> lower respiratory tract infection, <italic>KDIGO</italic> Kidney Disease Improving Global Outcomes, <italic>ED</italic> emergency department, <italic>DCF</italic> data collection form</p><p>
<sup>a</sup>We define an antibiotic-day as each day a participant receives any oral or intravenous antibiotics, excluding antibiotics given for non-infectious indications (e.g. rifaximin for hepatic encephalopathy) and antivirals</p><p>
<sup>b</sup>primary safety outcome</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Sample size determination and interim analyses</p></caption><table frame="hsides" rules="groups"><thead><tr><th>CONSORT</th><th>ProACT</th></tr></thead><tbody><tr><td>Sample size</td><td>1664</td></tr><tr><td>&#x02003;Determination</td><td>&#x02003;H1o: Procalcitonin guideline implementation does not reduce antibiotic exposure by Day 30. (superiority)<break/>&#x02003;H2o: Procalcitonin guideline implementation increases the proportion of subjects who experience a composite endpoint of adverse outcomes by Day 30, by &#x02265;4.5%. (non-inferiority)<break/>&#x02003;&#x02003;&#x025aa; Sample size is driven by H2o<break/>&#x02003;&#x02003;&#x025aa; 4.5% non-inferiority margin<break/>&#x02003;&#x02003;&#x025aa; &#x02265; 80% power, 1-sided alpha of 0.05<break/>&#x02003;&#x02003;&#x025aa; Lost to follow up and composite endpoint rates at 2nd interim data safety monitoring board meeting at ~2/3 accrual (April 2017)</td></tr><tr><td>&#x02003;Interim analyses and stopping rules</td><td>&#x02003;Two interim analyses and one final analysis, approximately evenly spaced<break/>&#x02003;O-Brien and Fleming stopping boundaries</td></tr></tbody></table></table-wrap>
<table-wrap id="Tab5"><label>Table 5</label><caption><p>Randomization, blinding, and statistical methods</p></caption><table frame="hsides" rules="groups"><thead><tr><th>CONSORT</th><th>ProACT</th></tr></thead><tbody><tr><td colspan="2">Randomization</td></tr><tr><td>&#x02003;Sequence generation</td><td>Patient-level, permuted block design<break/>Stratified by center, race, age<break/>Randomized equally to each study arm</td></tr><tr><td>&#x02003;Allocation concealment</td><td>Central Web-based randomization, accessible 24&#x000a0;h/day</td></tr><tr><td>&#x02003;Implementation</td><td>Local center staff enroll patients via Web-based randomization system<break/>Web-based system then assigns patients to trial arm, based on computer generated allocation sequence</td></tr><tr><td>Blinding</td><td>Statistical analysis and post-discharge outcome assessment staff are blinded to study arm<break/>By arm outcome data restricted to unblinded statistician and data safety monitoring board</td></tr><tr><td>Statistical methods</td><td>Intention-to-treat, as per pre-established analysis plan (primary analysis)<break/>Per-protocol analysis, where procalcitonin guideline is followed</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec4"><title>Participants (patients)</title><sec id="Sec5"><title>Inclusion criteria</title><p id="Par17">Study staff enroll adult ED patients with a primary clinical diagnosis of acute LRTI, where the treating clinician is willing to consider procalcitonin in antibiotic decision making (Table <xref rid="Tab1" ref-type="table">1</xref>). By targeting encounters where the clinician has not already decided to give or withhold antibiotics, we seek to enroll LRTI cases where clinical uncertainty exists.</p></sec><sec id="Sec6"><title>Exclusion criteria</title><p id="Par18">We exclude patients with conditions where (1) physicians are unlikely to withhold antibiotics (e.g., patients receiving endotracheal ventilation), (2) procalcitonin can be elevated without bacterial infection (e.g., recent surgery), and (3) follow-up would be difficult (e.g., prisoners, homeless) (Table <xref rid="Tab1" ref-type="table">1</xref>).</p></sec></sec><sec id="Sec7"><title>Participants (centers)</title><p id="Par19">We chose centers with evidence of commitment to LRTI quality care. All centers had achieved &#x0003e;96% compliance with all Joint Commission pneumonia core measures. We chose centers and center principal investigators based on clinical research experience, clinical expertise in LRTI management, ED volume, projected recruitment, ability to execute study procedures both in ED and in hospital, absence of routine procalcitonin use, and geographic diversity (<xref rid="Sec29" ref-type="sec">Appendix 1</xref>). Each center has clinical, laboratory, and health records systems that allow prompt notification of procalcitonin results. Centers are mostly urban academic hospitals.</p></sec><sec id="Sec8"><title>Interventions</title><sec id="Sec9"><title>Study arms</title><p id="Par20">In both arms (Table <xref rid="Tab2" ref-type="table">2</xref>) the bedside clinicians retain complete autonomy for all patient care decisions, and we disseminate national LRTI guidelines.</p><p id="Par21">We incorporate LRTI guideline recommendations in all study lectures, posters, and promotion tools. We provide relevant excerpts from the following guidelines: chronic obstructive pulmonary disease &#x02013; Global Initiative for Chronic Obstructive Lung Disease [<xref ref-type="bibr" rid="CR37">37</xref>]; asthma &#x02013; National Asthma Education and Prevention Program&#x02019;s Expert Panel Report 3 [<xref ref-type="bibr" rid="CR38">38</xref>], Global Initiative for Asthma [<xref ref-type="bibr" rid="CR39">39</xref>]; acute bronchitis &#x02013; Center for Disease Control/American College of Physicians guidelines [<xref ref-type="bibr" rid="CR40">40</xref>]; community-acquired pneumonia &#x02013; Infectious Diseases Society of America/American Thoracic Society guidelines [<xref ref-type="bibr" rid="CR24">24</xref>] (Fig. <xref rid="Fig1" ref-type="fig">1</xref>, left panel).<fig id="Fig1"><label>Fig. 1</label><caption><p>ProACT guidelines. The ProACT Coordinating Center provided posters of this Figure to all centers. Other study education, in-service training, and promotion materials contain the same content</p></caption><graphic xlink:href="12873_2017_138_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec10"><title>Intervention</title><p id="Par22">The intervention consists of reporting the procalcitonin results and guideline (Fig. <xref rid="Fig1" ref-type="fig">1</xref>, right panel) to clinicians. The same procalcitonin guideline is provided with both the initial and serial procalcitonin measurements - withhold or cease antibiotics if low, administer or continue if high. Participants have blood drawn for a procalcitonin level in the ED, and if hospitalized, 6&#x02013;24&#x000a0;h after the initial ED blood draw, and on Days 3, 5, and 7 if still in hospital and on antibiotics.</p><p id="Par23">We used several implementation strategies, centered around a primary message of &#x0201c;Please look at the procalcitonin value and guideline recommendation, but the final antibiotic decision is entirely yours.&#x0201d; With coordinating center support and tools, each site conducted background education and in-service training prior to study launch, and during the trial. All clinicians involved in antibiotic prescription for LRTI, including residents, hospitalists, primary care physicians, nurse practitioners, and physician assistants were targeted for in-service training. To promote easy reminders we embedded the procalcitonin information into the electronic health record of each site where feasible (<xref rid="Sec30" ref-type="sec">Appendix 2</xref>). This approach mimics how clinicians often receive laboratory test data with range-based interpretation, such as with troponin and d-dimer. Lastly, coordinators are trained to identify the key clinician with primary responsibility for antibiotic decision making, inform the clinician the procalcitonin information is available, and not otherwise influence care. In the ED, coordinators ensure clinicians quickly (&#x0003c; 1&#x000a0;h goal) receive the procalcitonin information. For patients admitted to hospital, coordinators inform hospital clinicians of the ED procalcitonin information and when serial procalcitonin results are available. Our intent is to mimic how a hospital might typically deploy quality improvement staff when introducing a new intervention. The final decision to order antibiotics is at the discretion of the treating clinician.</p></sec><sec id="Sec11"><title>Usual care</title><p id="Par24">Study personnel solely collect data and biologic specimens in usual care arm participants. We also sought to minimize contamination (procalcitonin use in usual care). At study launch, no center routinely used procalcitonin, only 2 centers had procalcitonin clinically available, and no LRTI guidelines recommended routine clinical use of procalcitonin.</p></sec><sec id="Sec12"><title>Standardization</title><p id="Par25">To standardize study procedures, we provide standardized training and materials plus continuous coordinating center support. We conducted a group investigator and coordinator training meeting at study launch, and individual sessions for two centers that were added subsequently. Training materials are available on the study website. Regular center visits, newsletters, around-the-clock coordinating center access, center monitoring, protocol delivery and procalcitonin guideline adherence reports and feedback were used to further enhance standardization.</p><p id="Par26">To standardize procalcitonin measurement, bioM&#x000e9;rieux provided the procalcitonin assay equipment, installation, and in-service training. We provided centers with a packet that outlined test result reporting procedures, troubleshooting procedures, frequently asked questions, and study contact information. Each center&#x02019;s Clinical Laboratory Improvement Amendments (CLIA) certified laboratory measured procalcitonin from plasma [<xref ref-type="bibr" rid="CR41">41</xref>] or serum [<xref ref-type="bibr" rid="CR42">42</xref>] samples, using a 1-step enzyme immunoassay sandwich method on bioM&#x000e9;rieux VIDAS or mini-VIDAS immunoanalyzers with an analytic range of 0.05&#x02013;200&#x000a0;ng/ml [<xref ref-type="bibr" rid="CR43">43</xref>]. To ensure accurate testing, each center performed standard instrument calibration procedures, analyzed two levels of quality control materials with each sample run, and at minimum biannually assessed assay linearity [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Additionally, twelve centers annually participated in a College of American Pathologists (CAP) proficiency testing program for procalcitonin, the American Proficiency Institute program, or conducted external peer (inter-laboratory) testing [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Procalcitonin levels remain stable under multiple freeze/thaw, storage, and temperature conditions [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR47">47</xref>].</p></sec><sec id="Sec13"><title>Adherence</title><p id="Par27">Our overall adherence approach is similar to many quality improvement programs. This design balances enforcement strategies not reproducible in routine care with a completely hands-off strategy that risks trial failure due to study unawareness [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>].</p><p id="Par28">For each study procalcitonin blood draw, we track the times for sample collection, and times from sample collection to clinician notification of procalcitonin information. We promote adherence to the study intervention with regular feedback to each center, and identify solutions for rectifying non-adherence.</p><p id="Par29">We track clinician adherence to the procalcitonin antibiotic guideline. If antibiotics are prescribed or continued when procalcitonin is low, coordinators query the clinician and record the reasons for non-adherence. We promote adherence to the procalcitonin guideline with regular feedback and discussion with each center. To increase study awareness and guideline adherence, centers in-service trained all clinician groups with primary responsibility for antibiotic prescription for LRTI. Upon discharge from ED or hospital, participants receive a packet that includes a letter to their primary care physician with a study synopsis, their last procalcitonin result, and the procalcitonin guideline.</p></sec></sec><sec id="Sec14"><title>Outcomes</title><sec id="Sec15"><title>Primary</title><p id="Par30">Our primary outcome is total antibiotic exposure, defined as the total number of antibiotic days by Day 30 (Table <xref rid="Tab3" ref-type="table">3</xref>). We define an antibiotic day as each day a subject receives any oral or intravenous antibiotic, excluding antibiotics given for non-infectious indications (e.g. rifaximin for hepatic encephalopathy) and antiviral agents.</p><p id="Par31">Our primary safety outcome is a combined endpoint of adverse outcomes that could be attributable to withholding antibiotics in LRTI. The individual outcomes are death, septic shock (vasopressor use), mechanical ventilation via endotracheal tube, renal failure (Kidney Disease: Improving Global Outcomes stage 3 &#x02013; new renal replacement therapy, tripling of baseline creatinine, or serum creatinine &#x02265;4.0&#x000a0;mg/dL [<xref ref-type="bibr" rid="CR50">50</xref>]), lung abscess/empyema, development of pneumonia in non-pneumonia LRTI, and hospital readmission, by day 30. Occurrence of one or more of these outcomes by day 30 will count as reaching the primary safety outcome. We will also examine each outcome individually. Although these outcomes are of different gravity, if any one of them were to occur, clinicians and patients would likely believe the procalcitonin guideline failed, and that antibiotics should have been provided. We therefore use a combined endpoint to capture each such adverse outcome.</p></sec><sec id="Sec16"><title>Secondary</title><p id="Par32">Secondary outcomes include antibiotic initiation by the initial ED clinician, hospital length of stay, 90&#x000a0;day and 1&#x000a0;year mortality, ICU admission and subsequent ED visits by Day 30, and quality of life at day 15 and day 30 (Table <xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec17"><title>Data quality methods</title><p id="Par33">We monitor data quality using web-based data collection, automated queries, and center monitoring visits, and provide structured data collection training to centers prior to study initiation. Coordinating center staff blinded to study arm conduct follow-up calls to determine post-discharge outcomes, using a structured interview process. To facilitate participant recall and retention, we conduct calls at both day 15 and day 30, provide an antibiotic diary at discharge, and obtain multiple contact phone numbers at enrollment. In 2016, we added text messaging, email, and postal mail follow-up methods.</p></sec></sec><sec id="Sec18"><title>Sample size</title><sec id="Sec19"><title>Determination</title><p id="Par34">ProACT will test the following two null hypotheses.<list list-type="bullet"><list-item><p id="Par35">
<italic>H1o</italic>: Procalcitonin guideline implementation does not reduce or increase antibiotic exposure by Day 30.</p></list-item><list-item><p id="Par36">
<italic>H2o</italic>: Procalcitonin guideline implementation increases the proportion of subjects who experience a composite endpoint of adverse outcomes by Day 30, by &#x02265;4.5%.</p></list-item></list>
</p><p id="Par37">We computed our original sample size of 1514 participants based on the difference in proportions of the composite adverse outcomes endpoint between the two arms in H2o. Our power calculations accounted for two interim analyses at approximately 1/3 and 2/3 enrollment with stopping boundaries calculated using the O&#x02019;Brien and Fleming method, &#x02265; 80% power to reject H2o, significance at the 0.05 level, a predefined 4.5% non-inferiority margin, and assuming an 11% adverse outcomes by Day 30 event rate in the usual care arm [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>], and ~10% loss to follow up rate. We thus calculated sample size under assumptions of event and lost to follow up rates, and also prospectively monitored both rates with an intent to recalculate and adjust sample size as necessary. In April 2017, the data and safety monitoring board held the second interim analysis meeting, and approved an increase of sample size to 1664 participants (Table <xref rid="Tab4" ref-type="table">4</xref>).</p><p id="Par38">The CONSORT extension for noninferiority trials notes that an overly large non-inferiority margin risks accepting a truly inferior treatment as noninferior, while a very small margin may produce inconclusive results, requiring an extremely large trial to achieve adequate power [<xref ref-type="bibr" rid="CR36">36</xref>]. We chose the smallest non-inferiority margin feasible within our funding structure, approximately half that of the margins recommended by the Infectious Diseases Society of America recommendation for non-inferiority trials assessing antibiotic treatment for community-acquired pneumonia, and the margins used in two large trials of procalcitonin antibiotic guidance [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR53">53</xref>].</p></sec><sec id="Sec20"><title>Interim analyses and stopping rules</title><p id="Par39">We submit data to an independent, multidisciplinary data safety and monitoring board for interim analyses on a predefined schedule and with a priori stopping rules. Before trial completion, only the board and designated study statistician see per-arm outcome data; the board may recommend stopping enrollment for any reason including efficacy, harm, or futility.</p><p id="Par40">Pre-established statistical plans and oversight committee charters mitigate concerns of spurious early cessation [<xref ref-type="bibr" rid="CR54">54</xref>].</p></sec></sec><sec id="Sec21"><title>Randomization</title><sec id="Sec22"><title>Sequence generation</title><p id="Par41">ProACT randomizes at the patient level, with 1:1 study arm allocation using a computer generated, permuted block design, stratified by center, race, and age (Table <xref rid="Tab5" ref-type="table">5</xref>).</p></sec><sec id="Sec23"><title>Allocation concealment</title><p id="Par42">We assure concealment via an automated centralized assignment system. Only after enrollment does the system assign a study arm.</p></sec><sec id="Sec24"><title>Implementation</title><p id="Par43">All participants who give consent for participation, fulfill inclusion criteria, and have no exclusion criteria are randomized. Coordinators enter participant information into the web-based data collection form and receive from the randomization system a study ID number and treatment assignment. There is no influence on randomization by the principal investigator, center study team, or the ProACT coordinating center.</p></sec></sec><sec id="Sec25"><title>Blinding</title><p id="Par44">Due to the nature of the intervention, neither the treating clinician nor the study staff can be blinded to allocation. Statistical analysis and post-discharge outcome assessment staff are blinded to allocation. We restrict access to unblinded data to a designated study statistician and data safety and monitoring board.</p></sec><sec id="Sec26"><title>Statistical methods</title><p id="Par45">An independent statistician blinded to treatment allocation will conduct analyses using a pre-established statistical plan. The primary analysis is an intent-to-treat (ITT) analysis, for both hypotheses. ITT can bias towards no difference, which may lead to a false rejection of H2o, which uses a non-inferiority design. We therefore will also perform per-protocol analyses where the procalcitonin guideline was followed, as per CONSORT recommendations [<xref ref-type="bibr" rid="CR36">36</xref>]. We will summarize baseline characteristics by study arm, and will test the primary hypotheses for significance at the 0.05 level.</p><p id="Par46">For H1o, we will compare the mean number of total antibiotic-days by Day 30 using two-sample t-test, or a nonparametric counterpart if data distribution is not normal, and report two-sided <italic>p</italic>-values for significance. In the U.S., antibiotic use for LRTI is high, and our design excludes common conditions where procalcitonin can be high without infection. Given these two conditions, we believed procalcitonin would not increase antibiotic use over an already high baseline, and initially chose one-sided significance testing. To be conservative and allow for the possibility of increased antibiotic use in the intervention arm, we will conduct and report two-sided <italic>p</italic>-values. As sample size is driven by the larger requirements of noninferiority testing for H2o, we are well powered to test H1o.</p><p id="Par47">For H2o, we will compare the difference in proportions of the composite adverse outcomes endpoint, relative to a 4.5% non-inferiority margin, and construct a two-sided 95% confidence interval for the difference in proportions. We will declare non-inferiority if the upper limit of the confidence interval is below 4.5%. Non-inferiority hypothesis testing is one-sided. We will report results in accordance with the CONSORT statements.</p></sec></sec><sec id="Sec27"><title>Discussion</title><p id="Par48">ProACT is the first multicenter U.S. randomized trial of procalcitonin. In designing the trial, we considered three key issues &#x02013; choice of eligibility criteria, choice of control arm, and approach to guideline implementation.</p><p id="Par49">Tests should only be obtained if results may change management [<xref ref-type="bibr" rid="CR55">55</xref>]. We therefore designed eligibility criteria to select patients whose care could reasonably be impacted by procalcitonin guidance. In particular, we targeted those patients for whom clinicians were willing to consider procalcitonin in their antibiotic decision making. In other words, patient encounters where a degree of clinical indecision exists, and thus an additional diagnostic might assist decision making, rather than only add cost.</p><p id="Par50">Trials should test novel interventions on a background of &#x0201c;best care&#x0201d;. We chose centers with evidence of commitment to LRTI quality care, and disseminated national LRTI guidelines to promote best practice. This approach balances the control arm extremes of &#x0201c;wild type&#x0201d; usual care, versus an &#x0201c;active control&#x0201d; arm with interventional enforcement, consistent with the NIH conference on Considering Usual Medical Care in Clinical Trial Design recommendations [<xref ref-type="bibr" rid="CR56">56</xref>].</p><p id="Par51">We chose a guideline implementation approach generalizable to U.S. clinical practice. A key difference between ProACT and the largest European LRTI trial is that the guideline recommendation is not deployed using coordinating center &#x0201c;enforcement methods&#x0201d; [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Instead, to facilitate implementation into routine care, we provide background education and in-service training, embed the procalcitonin results and guideline into the electronic health records and clinical laboratories of study centers, and use coordinator reminders to ensure information receipt. This approach more closely reflects how procalcitonin guidance would be received and used by clinicians in U.S. practice.</p></sec><sec id="Sec28"><title>Conclusion</title><p id="Par52">ProACT will provide generalizable evidence on the impact of a procalcitonin guideline, implemented with basic reproducible strategies, on antibiotic exposure and safety in U.S. patients with lower respiratory tract infection.</p></sec></body><back><app-group><app id="App1"><sec id="Sec29"><title>Appendix 1</title><p id="Par59">
<table-wrap id="Tab6"><label>Table 6</label><caption><p>ProACT Centers and Investigators</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Center</th><th># hospital beds</th><th>Urbanicity</th><th>Teaching status</th><th>Ownership</th><th>City, State</th></tr></thead><tbody><tr><td>Beth Israel Deaconess Medical Center</td><td>602</td><td>Urban</td><td>Large teaching</td><td>Nonprofit</td><td>Boston, MA</td></tr><tr><td>Brigham and Women&#x02019;s Hospital</td><td>763</td><td>Urban</td><td>Large teaching</td><td>Nonprofit</td><td>Boston, MA</td></tr><tr><td>Detroit Receiving Hospital</td><td>225</td><td>Urban</td><td>Large teaching</td><td>Profit</td><td>Detroit, MI</td></tr><tr><td>Essentia Health St. Mary&#x02019;s Medical Center</td><td>545</td><td>Rural</td><td>Small teaching</td><td>Nonprofit</td><td>Duluth, MN</td></tr><tr><td>Hershey Medical Center</td><td>454</td><td>Urban</td><td>Large teaching</td><td>Nonprofit</td><td>Hershey, PA</td></tr><tr><td>Maricopa Medical Center</td><td>275</td><td>Urban</td><td>Large teaching</td><td>Government</td><td>Maricopa. AZ</td></tr><tr><td>Massachusetts General Hospital</td><td>941</td><td>Urban</td><td>Large teaching</td><td>Nonprofit</td><td>Boston, MA</td></tr><tr><td>Norwalk Hospital</td><td>261</td><td>Urban</td><td>Large teaching</td><td>Nonprofit</td><td>Norwalk, CT</td></tr><tr><td>Ohio State University Hospital</td><td>850</td><td>Urban</td><td>Large teaching</td><td>Government</td><td>Columbus, OH</td></tr><tr><td>University of Alabama Hospital</td><td>997</td><td>Urban</td><td>Large teaching</td><td>Government</td><td>Birmingham, AL</td></tr><tr><td>University of California Irvine Medical Center</td><td>350</td><td>Urban</td><td>Large teaching</td><td>Government</td><td>Irvine, CA</td></tr><tr><td>University of Maryland Medical Center</td><td>771</td><td>Urban</td><td>Large teaching</td><td>Nonprofit</td><td>Baltimore, MD</td></tr><tr><td>UPMC Mercy</td><td>419</td><td>Urban</td><td>Large teaching</td><td>Nonprofit</td><td>Pittsburgh, PA</td></tr><tr><td>UPMC Presbyterian</td><td>795</td><td>Urban</td><td>Large teaching</td><td>Nonprofit</td><td>Pittsburgh, PA</td></tr></tbody></table><table-wrap-foot><p>We defined teaching status using the resident-to-bed ratio, classifying hospitals as nonteaching if they had no resident trainees, small teaching if the ratio was more than zero and less than 0.2, and large teaching if the ratio was 0.2 or greater [<xref ref-type="bibr" rid="CR58">58</xref>]</p><p>Beth Israel Deaconess Medical Center: Michael Donnino; Brigham and Women&#x02019;s Hospital: Peter Hou; Detroit Receiving Hospital: Robert Sherwin; Essentia Health St. Mary&#x02019;s Medical Center: John Holst; Hershey Medical Center: Colleen Rafferty, Daniel Rodgers; Maricopa Medical Center: William Dachman, Frank LoVecchio; Massachusetts General Hospital: Michael Filbin; Norwalk Hospital: Jonathan Fine, Jean Hammel; Ohio State University Hospital: Matthew Exline, Lauren Southerland; University of Alabama Hospital: Michael Kurz, David McCullum; University of California Irvine Medical Center: Shahram Lotfipour; University of Maryland Medical Center: Gentry Wilkerson; University of Pittsburgh Medical Center Mercy Hospital: Heather Prunty, Brian Suffoletto; University of Pittsburgh Medical Center Presbyterian Hospital: Aaron Brown, Franziska Jovin</p></table-wrap-foot></table-wrap>
</p></sec></app><app id="App2"><sec id="Sec30"><title>Appendix 2</title><p id="Par60">
<table-wrap id="Tab7"><label>Table 7</label><caption><p>Procalcitonin information delivery methods</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Center</th><th>PCT Delivery Method</th><th>EHR Type</th><th>Laboratory Information System</th></tr></thead><tbody><tr><td>Beth Israel Deaconess Medical Center</td><td>Paper</td><td>N/A</td><td>N/A</td></tr><tr><td>Brigham and Women&#x02019;s Hospital</td><td>Paper</td><td>N/A</td><td>N/A</td></tr><tr><td>Detroit Receiving Hospital</td><td>Paper</td><td>N/A</td><td>N/A</td></tr><tr><td>Essentia Health St. Mary&#x02019;s Medical Center</td><td>Electronic Health Record</td><td>Epic</td><td>Soft Lab</td></tr><tr><td>Hershey Medical Center</td><td>Electronic Health Record</td><td>Cerner</td><td>Sunquest</td></tr><tr><td>Maricopa Medical Center</td><td>Electronic Health Record</td><td>Epic</td><td>Epic Beaker</td></tr><tr><td>Massachusetts General Hospital</td><td>Electronic Health Record</td><td>Epic</td><td>Sunquest</td></tr><tr><td>Norwalk Hospital</td><td>Electronic Health Record</td><td>Epic</td><td>Sunquest</td></tr><tr><td>Ohio State University Hospital</td><td>Electronic Health Record</td><td>Epic</td><td>Sunquest</td></tr><tr><td>University of Alabama Hospital</td><td>Electronic Health Record</td><td>IMPACT</td><td>IMPACT</td></tr><tr><td>University of California Irvine Medical Center</td><td>Paper</td><td>N/A</td><td>N/A</td></tr><tr><td>University of Maryland Medical Center</td><td>Paper</td><td>N/A</td><td>N/A</td></tr><tr><td>UPMC Mercy</td><td>Electronic Health Record</td><td>Cerner</td><td>Sunquest</td></tr><tr><td>UPMC Presbyterian</td><td>Electronic Health Record</td><td>Cerner</td><td>Sunquest</td></tr></tbody></table><table-wrap-foot><p>
<italic>PCT</italic> procalcitonin, <italic>EHR</italic> electronic health record</p></table-wrap-foot></table-wrap>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>CAP</term><def><p id="Par5">College of American Pathologists</p></def></def-item><def-item><term>CLIA</term><def><p id="Par6">Clinical Laboratory improvement amendments</p></def></def-item><def-item><term>CONSORT</term><def><p id="Par7">Consolidated standards of reporting trials</p></def></def-item><def-item><term>ED</term><def><p id="Par8">Emergency department</p></def></def-item><def-item><term>ITT</term><def><p id="Par9">intent-to-treat</p></def></def-item><def-item><term>LRTI</term><def><p id="Par10">Lower respiratory tract infection</p></def></def-item><def-item><term>ProACT</term><def><p id="Par11">Procalcitonin antibiotic consensus trial</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>We thank the following University of Pittsburgh staff who contributed to the logistics and design of ProACT:</p><p>
<italic>CRISMA Center</italic>: Elizabeth Gimbel*, Kourtney Wofford*, Tammy Eaton* (Clinical Epidemiology), Melinda Carter and Vanessa Jackson (Molecular Lab Core), Caroline Pidro (Long Term Follow-Up Core), Edvin Music (Biostatistical and Data Management Core).</p><p>
<italic>MACRO Center</italic>: Ashley Ryman*, Denise Scholl, Barbara J. Early</p><p>*ProACT Coordinating Center</p><p>Dedicated to Linda Foa.</p><p>The complete list of ProACT Investigators is provided in <xref rid="Sec29" ref-type="sec">Appendix 1</xref>.</p><sec id="FPar1"><title>Funding</title><p id="Par53">This investigation was supported by the National Institute of Health, National Institute of General Medical Sciences grants 1R34GM102696&#x02013;01, 1R01GM101197-01A1. Procalcitonin assays were provided by bioM&#x000e9;rieux (Marcy-l&#x02019;&#x000c9;toile, France).</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par54">Not applicable.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>DTH, DCA, and DMY conceived and designed the study protocol. MJF and YD provided consultative guidance for the protocol. JAK and OMP provided laboratory expertise. CHC, FP, LAW, and JY provided statistical expertise. All authors contributed to the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par55">The University of Pittsburgh Institutional Review Board approved the ProACT trial.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par56">Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par57">David T. Huang receives grant funding from ThermoFisher for a study examining the microbiome in lower respiratory tract infection.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par58">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magill</surname><given-names>SS</given-names></name><name><surname>Edwards</surname><given-names>JR</given-names></name><name><surname>Beldavs</surname><given-names>ZG</given-names></name><name><surname>Dumyati</surname><given-names>G</given-names></name><name><surname>Janelle</surname><given-names>SJ</given-names></name><name><surname>Kainer</surname><given-names>MA</given-names></name><name><surname>Lynfield</surname><given-names>R</given-names></name><name><surname>Nadle</surname><given-names>J</given-names></name><name><surname>Neuhauser</surname><given-names>MM</given-names></name><name><surname>Ray</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Prevalence of antimicrobial use in US acute care hospitals, May-September 2011</article-title><source>JAMA</source><year>2014</year><volume>312</volume><fpage>1438</fpage><lpage>1446</lpage><pub-id pub-id-type="doi">10.1001/jama.2014.12923</pub-id><pub-id pub-id-type="pmid">25291579</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>DJ</given-names></name><name><surname>Hicks</surname><given-names>LA</given-names></name><name><surname>Pavia</surname><given-names>AT</given-names></name><name><surname>Hersh</surname><given-names>AL</given-names></name></person-group><article-title>Antibiotic prescribing for adults in ambulatory care in the USA, 2007-09</article-title><source>J Antimicrob Chemother</source><year>2014</year><volume>69</volume><fpage>234</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1093/jac/dkt301</pub-id><pub-id pub-id-type="pmid">23887867</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathan</surname><given-names>C</given-names></name><name><surname>Cars</surname><given-names>O</given-names></name></person-group><article-title>Antibiotic resistance--problems, progress, and prospects</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><fpage>1761</fpage><lpage>1763</lpage><pub-id pub-id-type="doi">10.1056/NEJMp1408040</pub-id><pub-id pub-id-type="pmid">25271470</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marston</surname><given-names>HD</given-names></name><name><surname>Dixon</surname><given-names>DM</given-names></name><name><surname>Knisely</surname><given-names>JM</given-names></name><name><surname>Palmore</surname><given-names>TN</given-names></name><name><surname>Fauci</surname><given-names>AS</given-names></name></person-group><article-title>Antimicrobial Resistance</article-title><source>JAMA</source><year>2016</year><volume>316</volume><fpage>1193</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.11764</pub-id><pub-id pub-id-type="pmid">27654605</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metlay</surname><given-names>JP</given-names></name><name><surname>Camargo</surname><given-names>CA</given-names><suffix>Jr</suffix></name><name><surname>MacKenzie</surname><given-names>T</given-names></name><name><surname>McCulloch</surname><given-names>C</given-names></name><name><surname>Maselli</surname><given-names>J</given-names></name><name><surname>Levin</surname><given-names>SK</given-names></name><name><surname>Kersey</surname><given-names>A</given-names></name><name><surname>Gonzales</surname><given-names>R</given-names></name></person-group><article-title>Cluster-randomized trial to improve antibiotic use for adults with acute respiratory infections treated in emergency departments</article-title><source>Ann Emerg Med</source><year>2007</year><volume>50</volume><fpage>221</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1016/j.annemergmed.2007.03.022</pub-id><pub-id pub-id-type="pmid">17509729</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Little</surname><given-names>P</given-names></name><name><surname>Rumsby</surname><given-names>K</given-names></name><name><surname>Kelly</surname><given-names>J</given-names></name><name><surname>Watson</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>M</given-names></name><name><surname>Warner</surname><given-names>G</given-names></name><name><surname>Fahey</surname><given-names>T</given-names></name><name><surname>Williamson</surname><given-names>I</given-names></name></person-group><article-title>Information leaflet and antibiotic prescribing strategies for acute lower respiratory tract infection: a randomized controlled trial</article-title><source>JAMA</source><year>2005</year><volume>293</volume><fpage>3029</fpage><lpage>3035</lpage><pub-id pub-id-type="doi">10.1001/jama.293.24.3029</pub-id><pub-id pub-id-type="pmid">15972565</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Ranji SR, Steinman MA, Shojania KG, Sundaram V, Lewis R, Arnold S, Gonzales R. Closing the Quality Gap: A Critical Analysis of Quality Improvement Strategies (Vol. 4: Antibiotic Prescribing Behavior). (2006).</mixed-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleming-Dutra</surname><given-names>KE</given-names></name><name><surname>Hersh</surname><given-names>AL</given-names></name><name><surname>Shapiro</surname><given-names>DJ</given-names></name><name><surname>Bartoces</surname><given-names>M</given-names></name><name><surname>Enns</surname><given-names>EA</given-names></name><name><surname>File</surname><given-names>TM</given-names><suffix>Jr</suffix></name><name><surname>Finkelstein</surname><given-names>JA</given-names></name><name><surname>Gerber</surname><given-names>JS</given-names></name><name><surname>Hyun</surname><given-names>DY</given-names></name><name><surname>Linder</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011</article-title><source>JAMA</source><year>2016</year><volume>315</volume><fpage>1864</fpage><lpage>1873</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.4151</pub-id><pub-id pub-id-type="pmid">27139059</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>B</given-names></name><name><surname>White</surname><given-names>JC</given-names></name><name><surname>Nylen</surname><given-names>ES</given-names></name><name><surname>Snider</surname><given-names>RH</given-names></name><name><surname>Becker</surname><given-names>KL</given-names></name><name><surname>Habener</surname><given-names>JF</given-names></name></person-group><article-title>Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis</article-title><source>J Clin Endocrinol Metab</source><year>2001</year><volume>86</volume><fpage>396</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">11232031</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assicot</surname><given-names>M</given-names></name><name><surname>Gendrel</surname><given-names>D</given-names></name><name><surname>Carsin</surname><given-names>H</given-names></name><name><surname>Raymond</surname><given-names>J</given-names></name><name><surname>Guilbaud</surname><given-names>J</given-names></name><name><surname>Bohuon</surname><given-names>C</given-names></name></person-group><article-title>High serum procalcitonin concentrations in patients with sepsis and infection</article-title><source>Lancet</source><year>1993</year><volume>341</volume><fpage>515</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(93)90277-N</pub-id><pub-id pub-id-type="pmid">8094770</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>L</given-names></name><name><surname>Gauvin</surname><given-names>F</given-names></name><name><surname>Amre</surname><given-names>DK</given-names></name><name><surname>Saint-Louis</surname><given-names>P</given-names></name><name><surname>Lacroix</surname><given-names>J</given-names></name></person-group><article-title>Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis</article-title><source>Clin Infect Dis</source><year>2004</year><volume>39</volume><fpage>206</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1086/421997</pub-id><pub-id pub-id-type="pmid">15307030</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>B</given-names></name><name><surname>Harbarth</surname><given-names>S</given-names></name><name><surname>Stolz</surname><given-names>D</given-names></name><name><surname>Bingisser</surname><given-names>R</given-names></name><name><surname>Mueller</surname><given-names>C</given-names></name><name><surname>Leuppi</surname><given-names>J</given-names></name><name><surname>Nusbaumer</surname><given-names>C</given-names></name><name><surname>Tamm</surname><given-names>M</given-names></name><name><surname>Christ-Crain</surname><given-names>M</given-names></name></person-group><article-title>Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia</article-title><source>BMC Infect Dis</source><year>2007</year><volume>7</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-7-10</pub-id><pub-id pub-id-type="pmid">17335562</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Huang DT, Weissfeld LA, Kellum JA, Yealy DM, Kong L, Martino M, Angus DC, GenIMS Investigators. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med. 2008;52(1):48&#x02013;58.e2. doi:10.1016/j.annemergmed.2008.01.003. Epub 2008 Mar 17.</mixed-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luyt</surname><given-names>CE</given-names></name><name><surname>Guerin</surname><given-names>V</given-names></name><name><surname>Combes</surname><given-names>A</given-names></name><name><surname>Trouillet</surname><given-names>JL</given-names></name><name><surname>Ayed</surname><given-names>SB</given-names></name><name><surname>Bernard</surname><given-names>M</given-names></name><name><surname>Gibert</surname><given-names>C</given-names></name><name><surname>Chastre</surname><given-names>J</given-names></name></person-group><article-title>Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. <italic>Am.J Respir</italic></article-title><source>Crit Care Med</source><year>2005</year><volume>171</volume><fpage>48</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1164/rccm.200406-746OC</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuetz</surname><given-names>P</given-names></name><name><surname>Christ-Crain</surname><given-names>M</given-names></name><name><surname>Thomann</surname><given-names>R</given-names></name><name><surname>Falconnier</surname><given-names>C</given-names></name><name><surname>Wolbers</surname><given-names>M</given-names></name><name><surname>Widmer</surname><given-names>I</given-names></name><name><surname>Neidert</surname><given-names>S</given-names></name><name><surname>Fricker</surname><given-names>T</given-names></name><name><surname>Blum</surname><given-names>C</given-names></name><name><surname>Schild</surname><given-names>U</given-names></name><etal/></person-group><article-title>Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial</article-title><source>JAMA</source><year>2009</year><volume>302</volume><fpage>1059</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1001/jama.2009.1297</pub-id><pub-id pub-id-type="pmid">19738090</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Muller B. Procalcitonin-guidance of antibiotic therapy in community-acquired pneumonia - A randomized trial. Am J Respir Crit Care Med. 2006;174(1):84&#x02013;93. Epub 2006 Apr 7. <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/16603606">https://www.ncbi.nlm.nih.gov/pubmed/16603606</ext-link>.</mixed-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christ-Crain</surname><given-names>M</given-names></name><name><surname>Jaccard-Stolz</surname><given-names>D</given-names></name><name><surname>Bingisser</surname><given-names>R</given-names></name><name><surname>Gencay</surname><given-names>MM</given-names></name><name><surname>Huber</surname><given-names>PR</given-names></name><name><surname>Tamm</surname><given-names>M</given-names></name><name><surname>Muller</surname><given-names>B</given-names></name></person-group><article-title>Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial</article-title><source>Lancet</source><year>2004</year><volume>363</volume><fpage>600</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)15591-8</pub-id><pub-id pub-id-type="pmid">14987884</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stolz</surname><given-names>D</given-names></name><name><surname>Christ-Crain</surname><given-names>M</given-names></name><name><surname>Bingisser</surname><given-names>R</given-names></name><name><surname>Leuppi</surname><given-names>J</given-names></name><name><surname>Miedinger</surname><given-names>D</given-names></name><name><surname>Muller</surname><given-names>C</given-names></name><name><surname>Huber</surname><given-names>P</given-names></name><name><surname>Muller</surname><given-names>B</given-names></name><name><surname>Tamm</surname><given-names>M</given-names></name></person-group><article-title>Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy</article-title><source>Chest</source><year>2007</year><volume>131</volume><fpage>9</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1378/chest.06-1500</pub-id><pub-id pub-id-type="pmid">17218551</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yealy</surname><given-names>DM</given-names></name><name><surname>Fine</surname><given-names>MJ</given-names></name></person-group><article-title>Measurement of serum procalcitonin: a step closer to tailored care for respiratory infections?</article-title><source>JAMA</source><year>2009</year><volume>302</volume><fpage>1115</fpage><lpage>1116</lpage><pub-id pub-id-type="doi">10.1001/jama.2009.1318</pub-id><pub-id pub-id-type="pmid">19738100</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuetz</surname><given-names>P</given-names></name><name><surname>Christ-Crain</surname><given-names>M</given-names></name><name><surname>Wolbers</surname><given-names>M</given-names></name><name><surname>Schild</surname><given-names>U</given-names></name><name><surname>Thomann</surname><given-names>R</given-names></name><name><surname>Falconnier</surname><given-names>C</given-names></name><name><surname>Widmer</surname><given-names>I</given-names></name><name><surname>Neidert</surname><given-names>S</given-names></name><name><surname>Blum</surname><given-names>CA</given-names></name><name><surname>Schonenberger</surname><given-names>R</given-names></name><etal/></person-group><article-title>Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial</article-title><source>BMC Health Serv Res</source><year>2007</year><volume>7</volume><fpage>102</fpage><pub-id pub-id-type="doi">10.1186/1472-6963-7-102</pub-id><pub-id pub-id-type="pmid">17615073</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitts</surname><given-names>SR</given-names></name><name><surname>Pines</surname><given-names>JM</given-names></name><name><surname>Handrigan</surname><given-names>MT</given-names></name><name><surname>Kellermann</surname><given-names>AL</given-names></name></person-group><article-title>National trends in emergency department occupancy, 2001 to 2008: effect of inpatient admissions versus emergency department practice intensity</article-title><source>Ann Emerg Med</source><year>2012</year><volume>60</volume><fpage>679</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1016/j.annemergmed.2012.05.014</pub-id><pub-id pub-id-type="pmid">22727201</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Armour, S. U.S. Emergency-room visits keep climbing. Wall Street J. 2015. 1-24-2017. Ref Type: Magazine Article.</mixed-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emanuel</surname><given-names>EJ</given-names></name><name><surname>Pearson</surname><given-names>SD</given-names></name></person-group><article-title>Physician autonomy and health care reform</article-title><source>JAMA</source><year>2012</year><volume>307</volume><fpage>367</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">22274681</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandell</surname><given-names>LA</given-names></name><name><surname>Wunderink</surname><given-names>RG</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Bartlett</surname><given-names>JG</given-names></name><name><surname>Campbell</surname><given-names>GD</given-names></name><name><surname>Dean</surname><given-names>NC</given-names></name><name><surname>Dowell</surname><given-names>SF</given-names></name><name><surname>File</surname><given-names>TM</given-names><suffix>Jr</suffix></name><name><surname>Musher</surname><given-names>DM</given-names></name><name><surname>Niederman</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults</article-title><source>Clin Infect Dis</source><year>2007</year><volume>44</volume><issue>Suppl 2</issue><fpage>S27</fpage><lpage>S72</lpage><pub-id pub-id-type="doi">10.1086/511159</pub-id><pub-id pub-id-type="pmid">17278083</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Center for Disease Control and Prevention. Number and rate of discharges from short-stay hospitals and of days of care, with average length of stay and standard error, by selected first-listed diagnostic categories: United States, 2010. 2012. Ref Type: Online Source.</mixed-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spellberg</surname><given-names>B</given-names></name></person-group><article-title>The new antibiotic mantra-&#x0201c;Shorter Is Better&#x0201d;</article-title><source>JAMA Intern Med</source><year>2016</year><volume>176</volume><fpage>1254</fpage><lpage>1255</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2016.3646</pub-id><pub-id pub-id-type="pmid">27455385</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Branche</surname><given-names>AR</given-names></name><name><surname>Walsh</surname><given-names>EE</given-names></name><name><surname>Vargas</surname><given-names>R</given-names></name><name><surname>Hulbert</surname><given-names>B</given-names></name><name><surname>Formica</surname><given-names>MA</given-names></name><name><surname>Baran</surname><given-names>A</given-names></name><name><surname>Peterson</surname><given-names>DR</given-names></name><name><surname>Falsey</surname><given-names>AR</given-names></name></person-group><article-title>Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial</article-title><source>J Infect Dis</source><year>2015</year><volume>212</volume><fpage>1692</fpage><lpage>1700</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiv252</pub-id><pub-id pub-id-type="pmid">25910632</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kollef</surname><given-names>MH</given-names></name></person-group><article-title>Will procalcitonin reduce antibiotic use in intensive care?</article-title><source>Lancet</source><year>2010</year><volume>375</volume><fpage>435</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)60140-7</pub-id><pub-id pub-id-type="pmid">20097416</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talan</surname><given-names>DA</given-names></name></person-group><article-title>Procalcitonin of questionable value</article-title><source>Ann Emerg Med</source><year>2012</year><volume>60</volume><fpage>536</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1016/j.annemergmed.2012.02.033</pub-id><pub-id pub-id-type="pmid">23010185</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Dissel</surname><given-names>JT</given-names></name></person-group><article-title>Procalcitonin and other markers of infection. What should be their role in clinical practice?</article-title><source>Clin Microbiol Infect</source><year>2002</year><volume>8</volume><fpage>70</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1046/j.1469-0691.2002.00406.x</pub-id><pub-id pub-id-type="pmid">11952718</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">McDonagh M, Peterson K, Winthrop K, Cantor A, Holzhammer B, Buckley DI. Improving antibiotic prescribing for uncomplicated acute respiratory tract infections. 2016. <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK344270/">https://www.ncbi.nlm.nih.gov/books/NBK344270/</ext-link>.</mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">National Institute for Health and Care Excellence. Assessment of community-acquired pneumonia. Last updated 12/23/2016. 2016. 3&#x02013;2-2017. Ref Type: Electronic Citation.</mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">U.S.Food and Drug Administration. FDA clears test to help manage antibiotic treatment for lower respiratory tract infections and sepsis. 2017. 3&#x02013;2-2017. Ref Type: Online Source.</mixed-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boutron</surname><given-names>I</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Ravaud</surname><given-names>P</given-names></name></person-group><article-title>Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration</article-title><source>Ann Intern Med</source><year>2008</year><volume>148</volume><fpage>295</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-148-4-200802190-00008</pub-id><pub-id pub-id-type="pmid">18283207</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name></person-group><article-title>CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials</article-title><source>PLoS Med</source><year>2010</year><volume>7</volume><fpage>e1000251</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1000251</pub-id><pub-id pub-id-type="pmid">20352064</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piaggio</surname><given-names>G</given-names></name><name><surname>Elbourne</surname><given-names>DR</given-names></name><name><surname>Pocock</surname><given-names>SJ</given-names></name><name><surname>Evans</surname><given-names>SJ</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement</article-title><source>JAMA</source><year>2012</year><volume>308</volume><fpage>2594</fpage><lpage>2604</lpage><pub-id pub-id-type="doi">10.1001/jama.2012.87802</pub-id><pub-id pub-id-type="pmid">23268518</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Global Initiative For Chronic Obstructive Lung Disease. <ext-link ext-link-type="uri" xlink:href="http://goldcopd.org/">http://goldcopd.org/</ext-link>. 2017. 1&#x02013;24-2017. Ref Type: Electronic Citation.</mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">2007. Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma-summary report 38. J Allergy Clin Immunol. 120:S94&#x02013;138.</mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Global Initiative For Asthma. <ext-link ext-link-type="uri" xlink:href="http://ginasthma.org/">http://ginasthma.org/</ext-link>. 2017. 1&#x02013;24-2017. Ref Type: Electronic Citation.</mixed-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>AM</given-names></name><name><surname>Hicks</surname><given-names>LA</given-names></name><name><surname>Qaseem</surname><given-names>A</given-names></name></person-group><article-title>Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention</article-title><source>Ann Intern Med</source><year>2016</year><volume>164</volume><fpage>425</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.7326/M15-1840</pub-id><pub-id pub-id-type="pmid">26785402</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meisner</surname><given-names>M</given-names></name><name><surname>Tschaikowsky</surname><given-names>K</given-names></name><name><surname>Schnabel</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>J</given-names></name><name><surname>Katalinic</surname><given-names>A</given-names></name><name><surname>Schuttler</surname><given-names>J</given-names></name></person-group><article-title>Procalcitonin--influence of temperature, storage, anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentrations</article-title><source>Eur J Clin Chem Clin Biochem</source><year>1997</year><volume>35</volume><fpage>597</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">9298349</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riedel</surname><given-names>S</given-names></name><name><surname>Melendez</surname><given-names>JH</given-names></name><name><surname>An</surname><given-names>AT</given-names></name><name><surname>Rosenbaum</surname><given-names>JE</given-names></name><name><surname>Zenilman</surname><given-names>JM</given-names></name></person-group><article-title>Procalcitonin as a marker for the detection of bacteremia and sepsis in the emergency department</article-title><source>Am J Clin Pathol</source><year>2011</year><volume>135</volume><fpage>182</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1309/AJCP1MFYINQLECV2</pub-id><pub-id pub-id-type="pmid">21228358</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Schuetz, P., M. Christ-Crain, A. R. Huber, and B. Muller. 2009. Long-term stability of procalcitonin in frozen samples and comparison of Kryptor(R) and VIDAS(R) automated immunoassays. Clin.Biochem<italic>.</italic></mixed-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">College of American Pathologists. 2016 Surveys and Anatomic Pathology Education Programs. <ext-link ext-link-type="uri" xlink:href="http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/2016-surveys-catalog.pdf">http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/2016-surveys-catalog.pdf</ext-link>. Ref Type: Electronic Citation.</mixed-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="other">Linearity FD Procalcitonin bioMerieux VIDAS and miniVIDAS package insert. 2017. Carlsbad; Audit Micro Controls Inc. Ref Type: Generic. <ext-link ext-link-type="uri" xlink:href="http://www.auditmicro.com/linearity-fd-procalcitonin-biomerieux-vidas-and-minividas.html">http://www.auditmicro.com/linearity-fd-procalcitonin-biomerieux-vidas-and-minividas.html</ext-link>.</mixed-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">American Proficiency Institute Catalog of Programs. <ext-link ext-link-type="uri" xlink:href="https://www.api-pt.com/catalog.aspx">https://www.api-pt.com/catalog.aspx</ext-link>. Ref Type: Electronic Citation. Accessed 12 Aug 2017.</mixed-citation></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">Hedelius R, Daheshia M, Seda G. Thermal stability evaluation of procalcitonin, A biomarker and mediator of bacterial infection. Am J Respir Crit Care Med. 2013;187:A5984. Ref Type: Abstract.</mixed-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yealy</surname><given-names>DM</given-names></name><name><surname>Auble</surname><given-names>TE</given-names></name><name><surname>Stone</surname><given-names>RA</given-names></name><name><surname>Lave</surname><given-names>JR</given-names></name><name><surname>Meehan</surname><given-names>TP</given-names></name><name><surname>Graff</surname><given-names>LG</given-names></name><name><surname>Fine</surname><given-names>JM</given-names></name><name><surname>Obrosky</surname><given-names>DS</given-names></name><name><surname>Edick</surname><given-names>SM</given-names></name><name><surname>Hough</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>The emergency department community-acquired pneumonia trial: Methodology of a quality improvement intervention</article-title><source>Ann Emerg Med</source><year>2004</year><volume>43</volume><fpage>770</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1016/j.annemergmed.2003.09.013</pub-id><pub-id pub-id-type="pmid">15159711</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yealy</surname><given-names>DM</given-names></name><name><surname>Auble</surname><given-names>TE</given-names></name><name><surname>Stone</surname><given-names>RA</given-names></name><name><surname>Lave</surname><given-names>JR</given-names></name><name><surname>Meehan</surname><given-names>TP</given-names></name><name><surname>Graff</surname><given-names>LG</given-names></name><name><surname>Fine</surname><given-names>JM</given-names></name><name><surname>Obrosky</surname><given-names>DS</given-names></name><name><surname>Mor</surname><given-names>MK</given-names></name><name><surname>Whittle</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial</article-title><source>Ann Intern Med</source><year>2005</year><volume>143</volume><fpage>881</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-143-12-200512200-00006</pub-id><pub-id pub-id-type="pmid">16365469</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khwaja</surname><given-names>A</given-names></name></person-group><article-title>KDIGO clinical practice guidelines for acute kidney injury</article-title><source>Nephron Clin Pract</source><year>2012</year><volume>120</volume><fpage>c179</fpage><lpage>c184</lpage><pub-id pub-id-type="pmid">22890468</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="other">Huang, D. T., L. A. Weissfeld, J. A. Kellum, D. M. Yealy, L. Kong, M. Martino, and D. C. Angus. 2008. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann. Emerg. Med.</mixed-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindenauer</surname><given-names>PK</given-names></name><name><surname>Pekow</surname><given-names>PS</given-names></name><name><surname>Lahti</surname><given-names>MC</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Benjamin</surname><given-names>EM</given-names></name><name><surname>Rothberg</surname><given-names>MB</given-names></name></person-group><article-title>Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease</article-title><source>JAMA</source><year>2010</year><volume>303</volume><fpage>2359</fpage><lpage>2367</lpage><pub-id pub-id-type="doi">10.1001/jama.2010.796</pub-id><pub-id pub-id-type="pmid">20551406</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouadma</surname><given-names>L</given-names></name><name><surname>Luyt</surname><given-names>CE</given-names></name><name><surname>Tubach</surname><given-names>F</given-names></name><name><surname>Cracco</surname><given-names>C</given-names></name><name><surname>Alvarez</surname><given-names>A</given-names></name><name><surname>Schwebel</surname><given-names>C</given-names></name><name><surname>Schortgen</surname><given-names>F</given-names></name><name><surname>Lasocki</surname><given-names>S</given-names></name><name><surname>Veber</surname><given-names>B</given-names></name><name><surname>Dehoux</surname><given-names>M</given-names></name><etal/></person-group><article-title>Use of procalcitonin to reduce patients&#x02019; exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial</article-title><source>Lancet</source><year>2010</year><volume>375</volume><fpage>463</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)61879-1</pub-id><pub-id pub-id-type="pmid">20097417</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montori</surname><given-names>VM</given-names></name><name><surname>Devereaux</surname><given-names>PJ</given-names></name><name><surname>Adhikari</surname><given-names>NK</given-names></name><name><surname>Burns</surname><given-names>KE</given-names></name><name><surname>Eggert</surname><given-names>CH</given-names></name><name><surname>Briel</surname><given-names>M</given-names></name><name><surname>Lacchetti</surname><given-names>C</given-names></name><name><surname>Leung</surname><given-names>TW</given-names></name><name><surname>Darling</surname><given-names>E</given-names></name><name><surname>Bryant</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Randomized trials stopped early for benefit: a systematic review</article-title><source>JAMA</source><year>2005</year><volume>294</volume><fpage>2203</fpage><lpage>2209</lpage><pub-id pub-id-type="doi">10.1001/jama.294.17.2203</pub-id><pub-id pub-id-type="pmid">16264162</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cassel</surname><given-names>CK</given-names></name><name><surname>Guest</surname><given-names>JA</given-names></name></person-group><article-title>Choosing wisely: helping physicians and patients make smart decisions about their care</article-title><source>JAMA</source><year>2012</year><volume>307</volume><fpage>1801</fpage><lpage>1802</lpage><pub-id pub-id-type="doi">10.1001/jama.2012.476</pub-id><pub-id pub-id-type="pmid">22492759</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>L</given-names></name><name><surname>Zarin</surname><given-names>DA</given-names></name><name><surname>Emanuel</surname><given-names>EJ</given-names></name><name><surname>Friedman</surname><given-names>LM</given-names></name><name><surname>Chaudhari</surname><given-names>B</given-names></name><name><surname>Goodman</surname><given-names>SN</given-names></name></person-group><article-title>Considering usual medical care in clinical trial design</article-title><source>PLoS Med</source><year>2009</year><volume>6</volume><fpage>e1000111</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1000111</pub-id><pub-id pub-id-type="pmid">19787044</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barley</surname><given-names>EA</given-names></name><name><surname>Quirk</surname><given-names>FH</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name></person-group><article-title>Asthma health status measurement in clinical practice: validity of a new short and simple instrument</article-title><source>Respir Med</source><year>1998</year><volume>92</volume><fpage>1207</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1016/S0954-6111(98)90423-1</pub-id><pub-id pub-id-type="pmid">9926151</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Farrell</surname><given-names>MH</given-names></name><name><surname>Lave</surname><given-names>JR</given-names></name><name><surname>Angus</surname><given-names>DC</given-names></name><name><surname>Barnato</surname><given-names>AE</given-names></name></person-group><article-title>Organizational determinants of hospital end-of-life treatment intensity</article-title><source>Med Care</source><year>2009</year><volume>47</volume><fpage>524</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1097/MLR.0b013e31819261bd</pub-id><pub-id pub-id-type="pmid">19318999</pub-id></element-citation></ref></ref-list></back></article>